Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 549Carcinoma, Non-Small-Cell Lung 506Prostatic Neoplasms 335Colorectal Neoplasms 268Multiple Myeloma 267Neoplasms 259Leukemia, Myeloid, Acute 218Squamous Cell Carcinoma of Head and Neck 213Lung Neoplasms 206Neoplasm Metastasis 204Carcinoma, Hepatocellular 197Triple Negative Breast Neoplasms 172Melanoma 172Pancreatic Neoplasms 171Recurrence 153Ovarian Neoplasms 151Lymphoma 140Sarcoma 132Glioblastoma 132Brain Neoplasms 132Head and Neck Neoplasms 126Carcinoma, Renal Cell 126Leukemia, Lymphocytic, Chronic, B-Cell 125Stomach Neoplasms 123Lymphoma, Large B-Cell, Diffuse 123Rectal Neoplasms 106Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Uterine Cervical Neoplasms 101Urinary Bladder Neoplasms 101Myelodysplastic Syndromes 101

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Microsatellite-stable Colorectal Cancer × 1 year × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡